Trial Profile
Long-term Extension Study To Evaluate The Safety Of Fesoterodine In Japanese Pediatric Subjects With Symptoms Of Detrusor Overactivity Associated With A Neurological Condition (Neurogenic Detrusor Overactivity) Who Have Completed 24 Weeks Treatment In Study A0221047
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary)
- Indications Neurogenic bladder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 05 May 2020 Status changed from active, no longer recruiting to completed.
- 21 Apr 2020 Planned End Date changed from 30 Jun 2020 to 1 Apr 2020.
- 21 Apr 2020 Status changed from recruiting to active, no longer recruiting.